An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases-Reference-Cited by-同舟云学术

An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases

Published:2022-11 Issue: Volume:175 Page:254-262
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Dutriaux Caroline,Robert Caroline,Grob Jean-Jacques,Mortier Laurent,Dereure Olivier,Lebbe Céleste,Mansard Sandrine,Grange Florent,Neidhardt Eve-Marie,Lesimple Thierry,Machet Laurent,Bedane Christophe,Maillard Hervé,Dalac-Rat Sophie,Nardin Charlée,Szenik Alexandra,Denden Amine,Saiag Philippe

Funder

Roche

Pfizer

Meso Scale Diagnostics

Merck

Novartis Pharma

Amgen

Les Laboratories Pierre Fabre

Bristol-Myers Squibb

Incyte

Novartis

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference12 articles.

1. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO);Soffietti;Neuro Oncol,2017

2. A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): the Anti-PD1 Brain Collaboration (ABC);Long;J Clin Orthod,2017

3. Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: a case series;Holbrook;Cancer,2020

4. Dabrafenib plus trametinib in patients with BRAF V600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial;Davies;Lancet Oncol,2017

5. 3337 safety and effectiveness analysis of V600 BRAF-mutated metastatic melanoma (MM) patients (pts) from the dabrafenib (D) plus trametinib (T) named patient programme (NPP) – DESCRIBE II study;Atkinson;Eur J Cancer,2015

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel paradigm of therapeutic intervention for skin cancer: challenges and opportunities;Future Journal of Pharmaceutical Sciences;2024-09-02

2. Melanoma Management: Exploring Staging, Prognosis, and Treatment Innovations;International Journal of Molecular Sciences;2024-05-26

3. BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape;npj Precision Oncology;2024-04-16

4. COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma;Cancers;2023-09-06

5. Conditional Survival in Prostate Cancer in the Nordic Countries Elucidates the Timing of Improvements;Cancers;2023-08-16